<DOC>
	<DOCNO>NCT01174693</DOCNO>
	<brief_summary>The purpose study compare preventive effect stroke triflusal clopidogrel ischemic stroke patient base cytochrome P450 2C19 ( CYP2C19 ) polymorphism .</brief_summary>
	<brief_title>Comparison Triflusal Clopidogrel Secondary Prevention Stroke Based Genotyping</brief_title>
	<detailed_description>Clopidogrel anti-platelet activity irreversible inhibition P2Y12 platelet receptor . Clopidogrel must convert active metabolite order show anti-platelet activity . Hepatic CYP2C19 enzyme one key hepatic enzyme convert clopidogrel active metabolite genetic polymorphism relate clopidogrel resistance . CYP2C19 poor intermediate metabolizer group show reduced anti-platelet activity clopidogrel compare extensive metabolizer group . This study design prove superiority triflusal prevent recurrent stroke clopidogrel ischemic stroke patient poor intermediate metabolizer CYP2C19 polymorphism . Also plan prove clopidogrel resistance relate CYP2C19 polymorphism compare ischemic preventive effect clopidogrel group different CYP2C19 polymorphism .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Triflusal</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>1 . Patients noncardiogenic ischemic stroke TOAST classification within 30 day prior screen 2 . â‰¥ 20 year age ; adult , date signing inform consent 3 . Written inform consent 1 . History bleeding tendency recent major bleed within 2 week 2 . Chronic liver disease ( ALT &gt; 100 IU/L AST &gt; 100 IU/L ) renal dysfunction ( creatinine &gt; 4.0 mg/dl ) 3 . Thrombocytopenia ( platelet &lt; 100,000mm3 ) 4 . Any contraindication antiplatelet agent 5 . Severe congestive heart failure 6 . Patients need take anticoagulant two antiplatelet agent 7 . Severe concomitant disease expect survival less 2 year 8 . Pregnant nursing 9 . Any drug clinical trial within 30 day sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>prospective</keyword>
	<keyword>randomize</keyword>
	<keyword>open label</keyword>
	<keyword>multi-center</keyword>
	<keyword>double-blind CYP2C19 genotype</keyword>
</DOC>